Page last updated: 2024-11-08

cochlioquinone a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cochlioquinone A: from Helminthosporium sativum; competitive inhibitor of ivermectin binding; RN from Chem Abstract Index Guide 1990; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161747
CHEMBL ID2288168
CHEBI ID177074
MeSH IDM0181581

Synonyms (9)

Synonym
CHEBI:177074
[(2s,3r,4s)-2-[(3r,4ar,6ar,12s,12as,12br)-12-hydroxy-3-(2-hydroxypropan-2-yl)-6a,12b-dimethyl-8,11-dioxo-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthen-9-yl]-4-methylhexan-3-yl] acetate
32450-25-2
cochlioquinone a
CHEMBL2288168
coclioquinone a
bdbm50529935
DTXSID501346549
cochlioquinonea

Research Excerpts

Overview

Cochlioquinone A is a competitive inhibitor of specific [3H]ivermectin binding. This suggests that cochlioquinones A and ivermectins interact with the same membrane receptor.

ExcerptReferenceRelevance
"Cochlioquinone A is a competitive inhibitor of specific [3H]ivermectin binding suggesting that cochlioquinone A and ivermectin interact with the same membrane receptor."( Cochlioquinone A, a nematocidal agent which competes for specific [3H]ivermectin binding sites.
Bergstrom, AR; Frazier, EG; Goetz, MA; Liesch, JM; Schaeffer, JM; Williamson, JM, 1990
)
2.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxanesAny organic heteromonocyclic compoundthat is oxane or its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Diacylglycerol kinase alphaHomo sapiens (human)Ki2.26002.26002.79003.3200AID1613990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
phosphatidic acid biosynthetic processDiacylglycerol kinase alphaHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayDiacylglycerol kinase alphaHomo sapiens (human)
platelet activationDiacylglycerol kinase alphaHomo sapiens (human)
diacylglycerol metabolic processDiacylglycerol kinase alphaHomo sapiens (human)
glycerolipid metabolic processDiacylglycerol kinase alphaHomo sapiens (human)
lipid phosphorylationDiacylglycerol kinase alphaHomo sapiens (human)
intracellular signal transductionDiacylglycerol kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
ATP-dependent diacylglycerol kinase activityDiacylglycerol kinase alphaHomo sapiens (human)
calcium ion bindingDiacylglycerol kinase alphaHomo sapiens (human)
ATP bindingDiacylglycerol kinase alphaHomo sapiens (human)
phospholipid bindingDiacylglycerol kinase alphaHomo sapiens (human)
lipid bindingDiacylglycerol kinase alphaHomo sapiens (human)
kinase activityDiacylglycerol kinase alphaHomo sapiens (human)
alkylglycerol kinase activityDiacylglycerol kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytosolDiacylglycerol kinase alphaHomo sapiens (human)
plasma membraneDiacylglycerol kinase alphaHomo sapiens (human)
membraneDiacylglycerol kinase alphaHomo sapiens (human)
plasma membraneDiacylglycerol kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1577569Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability at 10 uM after 24 hrs by CCK8 assay relative to control
AID1613990Inhibition of DGKalpha in human erythrocytes using OAG as substrate preincubated for 1 min followed by OAG addition and measured after 8 mins in presence of [gamma-32P]ATP2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID1577568Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability at 10 uM after 24 hrs by CCK8 assay relative to control
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (41.67)18.2507
2000's4 (33.33)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.69 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]